Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Curr Pharm Des ; 21(9): 1124-33, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25312736

RESUMO

The ability of a human artery to pass through 150 million liters of blood sustaining 2 billion pulsations of blood pressure with minor deterioration depends on unique construction of the arterial wall. Viscoelastic properties of this construction enable to re-seal the occuring damages apparently without direct immediate participance of the constituent cells. Collagen structures are considered to be the elements that determine the mechanoelastic properties of the wall in parallel with elastin responsible for elasticity and resilience. Collagen scaffold architecture is the function-dependent dynamic arrangement of a dozen different collagen types composing three distinct interacting forms inside the extracellular matrix of the wall. Tightly packed molecules of collagen types I, III, V provide high tensile strength along collagen fibrils but toughness of the collagen scaffold as a whole depends on molecular bonds between distinct fibrils. Apart of other macromolecules in the extracellular matrix (ECM), collagen-specific interlinks involve microfilaments of collagen type VI, meshwork-organized collagen type VIII, and FACIT collagen type XIV. Basement membrane collagen types IV, XV, XVIII and cell-associated collagen XIII enable transmission of mechanical signals between cells and whole artery matrix. Collagen scaffold undergoes continuous remodeling by decomposition promoted with MMPs and reconstitution from newly produced collagen molecules. Pulsatile stress-strain load modulates both collagen synthesis and MMP-dependent collagen degradation. In this way the ECM structure becomes adoptive to mechanical challenges. The mechanoelastic properties of the arterial wall are changed in atherosclerosis concomitantly with collagen turnover both type-specific and dependent on the structure. Improving the feedback could be another approach to restore sufficient blood circulation.


Assuntos
Artérias/fisiologia , Aterosclerose/fisiopatologia , Membrana Basal/fisiologia , Elasticidade/fisiologia , Colágenos Associados a Fibrilas/fisiologia , Colágenos Fibrilares/fisiologia , Remodelação Vascular/fisiologia , Artérias/anatomia & histologia , Artérias/patologia , Aterosclerose/patologia , Matriz Extracelular/fisiologia , Humanos , Metaloproteinases da Matriz/sangue , Estresse Mecânico
2.
Bull Exp Biol Med ; 158(1): 104-8, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25403408

RESUMO

Test system ELISA-BMP-2 is developed for measuring recombinant human bone morphogenetic protein-2 in human and laboratory animal serum and plasma by sandwich ELISA. The test system has been used for studies of the kinetics of bone morphogenetic protein-2 release from collagen carrier in the presence of plasma proteins.


Assuntos
Proteínas Sanguíneas/química , Proteína Morfogenética Óssea 2/química , Colágeno/química , Portadores de Fármacos/química , Animais , Coloides , Ensaio de Imunoadsorção Enzimática , Humanos , Hidrogéis , Cinética , Coelhos , Ratos
3.
Prikl Biokhim Mikrobiol ; 50(2): 226-31, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25272743

RESUMO

The release kinetics of recombinant human bone morphogenic factor 2 (rhBMP-2) from collageneous hydrogel in the presence of human blood plasma have been studied. The expulsion of rhBMP-2 from the collagen-BMP-2 complex by the competitive adhesion of collagen-binding proteins penetrating from plasma was firstly recognized. It was experimentally proven that that blood plasma fibronectin is the main collagen-binding protein, which is responsible for the controlled release of rhBMP-2. As a result, a new collageneous hydrogel with the incorporation of fibronectin was created which retained rhBMP-2 for a twice longer period as compared to the ordinary collageneous hydrogel. A distinctive feature of this new collagen-fibronectin matrix is the slow release of rhBMP-2 in the first three days which allows for the avoiding of adverse effects in clinics caused by the rapid release of large amounts of rhBMP-2 from collageneous hydrogel.


Assuntos
Proteína Morfogenética Óssea 2/química , Colágeno/química , Fibronectinas/química , Preparações de Ação Retardada , Humanos , Hidrogéis/química , Cinética , Ligação Proteica , Proteínas Recombinantes/química , Engenharia Tecidual , Alicerces Teciduais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA